Tenovate (clobetasol propionate 0.05%) is a high-potency, Class I topical corticosteroid formulation indicated for the short-term treatment of severe, resistant inflammatory dermatoses unresponsive to lower-potency corticosteroids. It functions as a vasoconstrictive, anti-inflammatory, and antiproliferative agent, offering rapid symptomatic relief and disease modification in appropriate patient populations. Its efficacy is attributed to its significant glucocorticoid receptor affinity and potent inhibition of inflammatory mediators. This product card provides a comprehensive, evidence-based overview for healthcare professionals managing complex dermatological conditions.

Features

• Contains clobetasol propionate 0.05% as the active pharmaceutical ingredient
• Available in multiple formulations: ointment, cream, gel, solution, and foam
• Rapid cutaneous penetration with high receptor-binding affinity
• Formulated with optimized bases for enhanced drug delivery and patient compliance
• Manufactured under cGMP conditions with batch-to-batch consistency
• Standardized potency classification as a super-high-potency (Class I) corticosteroid
• Multiple package sizes (15g, 30g, 60g tubes; 50mL solutions) for flexible prescribing
• Alcohol-free options available for sensitive skin types
• Preservative-free formulations in select presentations
• White petrolatum base in ointment formulation for occlusive properties

Benefits

• Provides rapid relief from pruritus, erythema, and edema within 24-48 hours of initiation
• Effectively modifies disease course in treatment-resistant inflammatory conditions
• Reduces lichenification and plaque elevation in hyperkeratotic disorders
• Minimizes disease flares through potent anti-inflammatory action
• Offers formulation flexibility to match specific anatomical sites and patient preferences
• Enables shorter treatment duration compared to mid-potency corticosteroids due to superior efficacy

Common use

Tenovate is primarily indicated for short-term treatment of severe corticosteroid-responsive dermatoses including psoriasis (particularly plaque-type), refractory atopic dermatitis, lichen planus, discoid lupus erythematosus, and severe contact dermatitis. It is particularly valuable in managing hyperkeratotic conditions where penetration barriers exist. Off-label uses may include alopecia areata, vitiligo (with phototherapy), and granuloma annulare, though evidence varies. Clinical application should always consider the condition’s severity, treatment area, and patient-specific factors.

Dosage and direction

Apply a thin film to affected areas once or twice daily, depending on severity and physician recommendation. For most dermatoses, twice-daily application is initiated, with reduction to once daily upon improvement. The total weekly dosage should not exceed 50g for adults or proportionally less for pediatric patients. Treatment duration is typically limited to 2 consecutive weeks, with no more than 50g weekly. Occlusive dressings may be used for resistant plaques but increase systemic absorption risk. Wash hands after application unless treating hands. For scalp solutions, part hair and apply directly to lesions.

Precautions

Use with caution in pediatric patients due to increased skin surface area to body mass ratio. Avoid use on face, groin, axillae, or other intertriginous areas unless specifically directed. Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use. Discontinue if irritation develops. Not for ophthalmic use. Use sparingly on large body surface areas. Elderly patients may have increased susceptibility to skin atrophy. Patients with liver impairment may require monitoring. Do not use on broken skin or open wounds.

Contraindications

Hypersensitivity to clobetasol propionate or any formulation components. Contraindicated in rosacea, perioral dermatitis, acne vulgaris, and cutaneous infections (viral, fungal, or bacterial). Not recommended during pregnancy unless potential benefit justifies potential risk. Avoid use in patients with circulatory disorders. Contraindicated in patients with untreated systemic infections. Not for use under occlusive dressings in children. Avoid in patients with known adrenal suppression.

Possible side effect

Common: localized burning, stinging, itching, dryness, erythema, and folliculitis. Less frequent: skin atrophy, striae, telangiectasia, hypopigmentation, hypertrichosis, and miliaria. Rare: allergic contact dermatitis, secondary infection, and acneiform eruptions. Systemic effects may include HPA axis suppression, glucosuria, hypertension, and Cushing’s syndrome with excessive use. Pediatric patients may demonstrate increased susceptibility to systemic effects. Most local adverse effects are reversible upon discontinuation.

Drug interaction

No specific pharmacokinetic drug interactions documented. However, concomitant use with other corticosteroids (topical or systemic) may increase risk of systemic effects. Use with other potentially ototoxic or nephrotoxic drugs may theoretically increase risk when systemic absorption occurs. No known interactions with CYP450 enzymes. Caution advised when using with other topical medications that may enhance absorption or cause irritation.

Missed dose

Apply as soon as remembered unless close to next scheduled dose. Do not double application to make up for missed dose. Maintain regular application schedule. Brief interruptions in treatment are unlikely to significantly affect overall efficacy given the medication’s persistence in skin. If multiple doses are missed, consult prescribing physician for guidance on reinitiation strategy.

Overdose

Topical overdose may manifest as severe local skin reactions including intensified burning, peeling, and severe erythema. Systemic absorption in excessive amounts may produce symptoms of hypercorticism including moon face, central obesity, hypertension, and hyperglycemia. Treatment involves discontinuation of medication and supportive care. Acute topical overdose should be managed by cleansing the area. Systemic effects may require endocrinological evaluation and possible corticosteroid replacement therapy if HPA suppression occurs.

Storage

Store at controlled room temperature (20-25°C or 68-77°F). Excursions permitted between 15-30°C (59-86°F). Keep tube tightly closed when not in use. Protect from freezing and excessive heat. Do not store in bathroom where moisture may degrade product. Keep out of direct sunlight. Do not puncture or incinerate containers. Keep out of reach of children and pets. Discard any product that has changed color, consistency, or odor.

Disclaimer

This information is intended for healthcare professionals only. Treatment decisions must be made by qualified practitioners based on individual patient assessment. Product information may change; always consult current prescribing information before administration. This document does not replace professional medical judgment, diagnosis, or treatment. Patients should be advised to report any adverse reactions to their healthcare provider. Safety and efficacy in pregnancy, lactation, and pediatric populations have not been fully established.

Reviews

Clinical studies demonstrate 70-90% improvement in psoriasis patients within 2 weeks. Dermatologists consistently rate Tenovate as superior to other high-potency steroids for resistant plaques. Patient satisfaction surveys indicate high rates of symptom relief and quality of life improvement. Some reports note concerns about rebound flares upon discontinuation. Long-term safety data supports restricted duration use. Comparative trials show faster clearance rates versus betamethasone dipropionate and fluocinonide in plaque psoriasis.